ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2020
Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05411354 (Analyzing Clinical Trial Experiences of Prostate Cancer Patients To Determine How Trial Attributes Affect Completion Rates For Specific Demographic Groups), which is not on this map. Cited by 66 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Analyzing Clinical Trial Experiences of Prostate Cancer Patients To Determine How Trial Attributes Affect Completion Rates For Specific Demographic Groups
Who cites it
66 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Inclusivity in prostate cancer and exercise research: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Pooled it
- Recruitment, retention and reporting of variables related to ethnic diversity in randomised controlled trials: an umbrella review.BMJ open · 2024Pooled it
- Twenty-year trends in racial and ethnic enrollment in large diabetes randomized controlled trials.BMC medicine · 2022Pooled it
- Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020.Frontiers in oncology · 2021Pooled it
- Assessing Algorithmic Fairness With a Multimodal Artificial Intelligence Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III Trials.JCO clinical cancer informatics · 2025Trial
- Incorporating health literacy principles into the adaptation of a methods motivational interviewing approach for enrolling black adults in a pilot randomized trial.Scientific reports · 2025Trial
- Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP).The Journal of urology · 2024Trial
- The Effect of Racial Concordance on Patient Trust in Online Videos About Prostate Cancer: A Randomized Clinical Trial.JAMA network open · 2023Trial
- Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study.Cancer medicine · 2023Trial
- Design Characteristics and Survival Outcomes of Local Trials Supporting the Approval of Targeted Anticancer Drugs in China.Cancer medicine · 2026Article
- Biochemical recurrence following definitive treatment of prostate cancer in Brazil: a retrospective cohort study.BMC urology · 2026Observational
- A Cost-Analysis and Micro-Costing Study of the Man Van Project: Comparing Prostate-Specific Antigen Testing Via a Nurse-Led Mobile Service with Primary Care.PharmacoEconomics - open · 2026Article
- From prostate specific antigen to genomic signatures: Advances in biomarkers for prostate cancer diagnosis and prognosis.Translational oncology · 2026Review
- Physical Activity, Trust, and Research Participation Among Men From Minority Ethnic Backgrounds Living With Prostate Cancer: A Qualitative Study.Psycho-oncology · 2026Article
- Comment to: Socioeconomic inequities in prostate cancer care: private versus public treatment settings pose a significant impact on overall survival.Einstein (Sao Paulo, Brazil) · 2026Article
- Factors associated with clinical research participation among Medicare beneficiaries with prostate cancer in the United States.Frontiers in oncology · 2026Article
- Barriers and facilitators to prostate cancer healthcare in Black men in the UK: from diagnosis to survivorship.Journal of cancer survivorship : research and practice · 2025Article
- Reporting and representation of participant race and ethnicity in phase III clinical trials for solid tumors.Future science OA · 2025Article
- Rationale and protocol for a prospective clinical trial enrollment improvement hybrid study within a trial.Contemporary clinical trials communications · 2025Article
- Unveiling Factors Associated With Older Adult Accrual to Cancer Clinical Trials: Lessons From the ECOG-ACRIN Experience.Journal of the National Comprehensive Cancer Network : JNCCN · 2025Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundAlthough there are considerable racial and ethnic disparities in prostate cancer incidence and mortality in the United States and globally, clinical trials often do not reflect disease incidence across racial and ethnic subgroups. This study aims to comprehensively review the reporting of race and ethnicity data and the representation of race and ethnicity across prostate cancer treatment-, prevention-, and screening-based clinical trials.
methodsSeventy-two global phase III and IV prevention, screening, and treatment prostate cancer clinical trials with enrollment start dates between 1987 and 2016 were analyzed in this study, representing a total of 893,378 individual trial participants. Availability and representation of race and ethnicity data by trial funding type, temporal changes in the racial/ethnic diversity of participants, and geographic representation of countries were assessed.
resultsOf the 72 trials analyzed, 59 (81.9%) had available race data, and 11 (15.3%) of these trials additionally reported ethnicity. Of the trials reporting data, participants were overwhelmingly white men (with the highest proportion in U.S. nonpublicly funded trials), comprising over 96% of the study population. The proportion of white participants in prostate cancer clinical trials has remained at over 80% since 1990. Geographically, Africa and the Caribbean were particularly underrepresented with only 3% of countries included.
conclusionsTrial participants continue to be majority white despite the known racial disparities in prostate cancer clinical outcomes. IMPACT: Current and future trials must use novel recruitment strategies to ensure enrollment of underrepresented men. Targeting the inclusion of African and Caribbean medical centers is crucial to achieve equity in representation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.